2,518
Participants
Start Date
August 31, 2013
Primary Completion Date
October 30, 2016
Study Completion Date
October 30, 2016
Option B+
"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
Good Shepherd Hospital, Siteki
Siphofaneni, Siteki
Siteki PHU, Siteki
Family Life Association Clinic, Manzini
King Soghuza II PHU, Manzini
Lamvelase Clinic, Manzini
Luyengo Clinic, Manzini
Mankayane PHU, Manzini
Mbabane Government Hospital, Manzini
Mbikhwakhe Clinic, Manzini
MSF Matsapha, Manzini
Raleigh Fitkin Memorial Hospital, Manzini
United States Agency for International Development (USAID)
FED
Ministry of Health, Swaziland
OTHER_GOV
University of Cape Town
OTHER
Elizabeth Glaser Pediatric AIDS Foundation
OTHER
National Emergency Response Council on HIV and AIDS (NERCHA)
UNKNOWN
Columbia University
OTHER